urelumab (BMS-663513) / Ono Pharma, BMS 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
urelumab (BMS-663513) / BMS, Ono Pharma
NCT02845323: Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruiting
2
15
US
Nivolumab in combination with Urelumab, Opdivo, Nivolumab monotherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Urothelial Carcinoma, Bladder Cancer
07/24
12/24
NCT02451982: Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Recruiting
2
76
US
Cyclophosphamide, Cytoxan, CY, GVAX pancreatic cancer, GVAX, pancreatic tumor vaccine, Nivolumab, OPDIVO; BMS-936558; anti-PD1, Urelumab, BMS-663513; anti-CD137 Agonist, BMS-986253, anti-IL8 antibody; HuMax-IL8
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Bristol-Myers Squibb
Pancreatic Cancer
12/24
12/25
INTRUST, NCT03792724 / 2017-005106-35: Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors

Not yet recruiting
1/2
32
Europe
Urelumab + Nivolumab
Clinica Universidad de Navarra, Universidad de Navarra
Neoplasms
01/23
01/23
C4-MOSART, NCT03431948: Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

Completed
1
60
US
Nivolumab, OPDIVO, BMS-936558, Cabiralizumab, BMS-986227, FPA008, Urelumab, BMS-663513, Stereotactic Body Radiation Therapy
University of Chicago, Bristol-Myers Squibb
Cancer
02/20
04/22
NCT02658981: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Completed
1
63
US
Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, BMS-936558, Nivolumab, Pharmacological Study, Laboratory Biomarker Analysis, Anti-CD137, urelumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Bristol-Myers Squibb
Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
04/22
10/23

Download Options